We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cosentyx is the first biologic approved in China that specifically inhibits interleukin-17A (IL-17A), a cornerstone cytokine involved in the inflammation of psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)
Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1].